Prospective Study

Comparison of endoscopic ultrasound, computed tomography and magnetic resonance imaging in assessment of detailed structures of pancreatic cystic neoplasms

Chen Du, Ning-Li Chai, En-Qiang Linghu, Hui-Kai Li, Li-Hua Sun, Lei Jiang, Xiang-Dong Wang, Ping Tang, Jing Yang

Author contributions: Du C and Chai NL contributed equally to this work; Chai NL and Linghu EQ designed the research; Du C, Chai NL, Linghu EQ, Li HK, Sun LH, Jiang L, Wang XD, Tang P and Yang J performed the research; Du C, Sun LH and Jiang L analyzed the data; Du C wrote the paper; Chai NL and Linghu EQ made critical revision of the article for important intellectual content; Linghu EQ approved the final version of the article.

Supported by Scientific Research Fund of Army of China, No. 14BJZ01.

Institutional review board statement: This study was reviewed and approved by the Committee of Medical Ethics of Chinese People’s Liberation Army General Hospital.

Clinical trial registration statement: The study was registered at http://www.chictr.org.cn/showproj.aspx?proj=10604. The registration identification number is ChiCTR-OOC-15006118.

Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

Conflict-of-interest statement: There are no conflicts of interest in relation to this manuscript.

Data sharing statement: There are no additional data available in relation to this manuscript.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Unsolicited manuscript

Correspondence to: En-Qiang Linghu, PhD, Department of Gastroenterology and Hepatology, Chinese People’s Liberation Army General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China. linghuoqiang@vip.sina.com
Telephone: +86-10-68182255
Fax: +86-10-55499292

Received: January 5, 2017
Peer-review started: January 5, 2017
First decision: February 9, 2017
Revised: February 20, 2017
Accepted: March 15, 2017
Article in press: March 15, 2017
Published online: May 7, 2017

Abstract

AIM
To evaluate the advantages of endoscopic ultrasound (EUS) in the assessment of detailed structures of pancreatic cystic neoplasms (PCNs) compared to computed tomography (CT) and magnetic resonance imaging (MRI).

METHODS
All patients with indeterminate PCNs underwent CT, MRI, and EUS. The detailed information, including size, number, the presence of a papilla/nodule, the presence of a septum, and the morphology of the pancreatic duct of PCNs were compared among the three imaging modalities. The size of each PCN was determined...
This study was designed to evaluate the capabilities of imaging modalities in demonstrating pancreatic cystic neoplasms (PCNs) from other PCLs. Several studies compared the abilities of the three modalities in patients with PCNs. However, few published studies compared the diagnostic value of endoscopic ultrasound (EUS), computed tomography (CT), and magnetic resonance imaging (MRI) in the diagnosis of PCLs. Previous studies showed the capacity of EUS to show the detailed structures of PCNs, which may be related to its ability to show the detailed structures of pancreatic duct in patients with PCNs and compared the number of daughter cysts in mother cysts than CT (P = 0.003); however, there was no significant difference between EUS and MRI in assessing mother-daughter cysts (P = 0.254). The papilla/nodule detection rate by EUS was 35.3% (24/68), much higher than those by CT (5.8%, 3/52) and MRI (6.3%, 4/64). The detection rate of the septum by EUS was 60.3% (41/68), which was higher than those by CT (34.6%, 18/52) and by MRI (46.9%, 30/64); the difference between EUS and CT was significant (P = 0.02). The rate of visualizing the pancreatic duct using EUS was 100%, whereas using CT and MRI it was less than 10%.

CONCLUSION
EUS helps visualize the detailed structures of PCNs and has many advantages over CT and MRI. EUS is valuable in the diagnosis and assessment of PCNs.

Key words: Endoscopic ultrasound; Detailed structures; Computed tomography; Magnetic resonance imaging; Pancreatic cystic neoplasms

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: This study was designed to evaluate the advantages of endoscopic ultrasound (EUS) in the assessment of the detailed structures of pancreatic cystic neoplasms (PCNs) compared with computed tomography (CT) and MRI. Previous studies showed the advantages of EUS in the diagnosis of PCNs. Multiple published studies compared the diagnostic value of EUS, CT, and MRI in patients with PCNs. However, few studies compared the abilities of the three modalities to evaluate the detailed structures of PCNs. There are many studies about the diagnostic value of imaging modalities in pancreatic cystic lesions (PCLs), and several studies assessed their ability to differentiate PCNs from other PCLs. Several studies compared the abilities of imaging modalities in demonstrating daughter cysts.

INTRODUCTION
Pancreatic cystic lesions (PCLs) include true cysts, pseudocysts and cystic neoplasms. True cysts, most of which are congenital, and pseudocysts, which are primarily caused by inflammation or injury, are non-neoplastic cysts and are regarded as benign whereas cystic neoplasms have the potential to be malignant. Approximately 60% of PCLs are cystic tumors, followed by inflammation and trauma-related pseudocysts, which account for 30% [1]. The prevalence of pancreatic cystic neoplasms (PCNs) has been reported to range widely, from 0.21%-24.3% [2-4]. There are four main types of PCNs: serous cystic neoplasms (SCNs), mucinous cystic neoplasms (MCNs), intraductal papillary mucinous neoplasms (IPMNs), and solid pseudopapillary neoplasms (SPNs). Two additional, but relatively uncommon, types of PCNs include cystic neuroendocrine neoplasms (NEFs) and cystadenocarcinomas. Due to the malignant potential of PCNs, differentiating them from non-neoplastic cysts and benign PCNs is critical. Obtaining accurate diagnostic images of detailed anatomic structures will be useful in the classification of PCNs. Using such imaging modalities may aid in the appropriate diagnosis and help determine subsequent treatments [5].

In order to evaluate PCLs, various imaging modalities have been used, including ultrasound (US), computed tomography (CT), magnetic resonance imaging (MRI), endoscopic ultrasound (EUS), MR cholangiopancreatography (MRCP), positron emission computed tomography (PET) and endoscopic retrograde cholangiopancreatography (ERCP) [6-11]. CT and MRI have been the most frequently used imaging techniques in the diagnosis of PCLs [12]. However, using EUS has an advantage over using CT or MRI in distinguishing between benign PCLs and malignant or potentially malignant lesions [13,14]. The images produced using EUS are higher in resolution than those by CT or MRI, which we speculate may be related to its ability to show the detailed structures of PCNs.

There are multiple published studies comparing the diagnostic value of EUS, CT, and MRI in patients with PCNs. However, few studies have compared the capability of CT, MRI, and EUS to evaluate the detailed structures of PCNs. In this study, we investigated the capacity of EUS to evaluate cyst size, number, papillae/nodules, septum, and the morphology of the pancreatic duct in patients with PCNs and compared...
these results with those obtained using CT and MRI.

**MATERIALS AND METHODS**

This study was approved by the Ethical Committee of Chinese People's Liberation Army General Hospital.

**Patients**

All patients who presented to the Chinese PLA General Hospital in Beijing with suspected PCNs between April 2015 and November 2016 (n = 143) were prospectively evaluated for possible study enrollment. Of these, 73 patients had undergone surgery. The eligibility criteria for inclusion in this study included (1) being at least 18 years of age; (2) having the ability to consent to and undergo EUS examination with or without CT and MRI prior to surgery; and (3) pathologically diagnosed with PCNs. Patients were excluded if they could not independently provide informed consent, could not undergo anesthesia or endoscopic examination, had active acute pancreatitis or pancreatic necrosis, or had a coagulopathy. Patients were also excluded if they were pathologically diagnosed with non-neoplastic cystic lesions. A total of 68 patients who were pathologically diagnosed with PCNs were enrolled in the study.

**Study design**

Any patient who was suspected of having PCNs using imaging techniques was suggested to undergo CT, MRI, and EUS. CT and MRI scans were individually read by radiologists with more than 10 years of experience and by digestive physicians with more than 3 years of experience. The final report was determined after both the radiologist and digestive physician had separately analyzed the images and then come to an agreement. The agreements correlated well for both CT (κ = 0.797) and MRI (κ = 0.836). EUS procedures were performed by experts with at least 5 years of experience. Patients suspected of having PCNs with a malignant potential using imaging techniques, or those who refused to undergo EUS-guided ablation or imaging for surveillance, were recommended to undergo surgery. Once all of the confirmed PCNs were studied, the effectiveness of using EUS, CT, and MRI to evaluate the cysts was assessed.

**Definitions**

The largest diameter of each PCN was used to indicate its size. The following rules were used when comparing the ability of the different imaging modalities to assess cyst number and size: only the sizes of cysts that were visualized using all of the imaging techniques were analyzed. A single tumor with unilocular or multilocular cysts (a cyst in a cyst) and cysts that formed a cluster around a central scar (a cyst on a cyst) were both referred to as a mother-daughter cyst. The mother-daughter cyst was regarded as a cyst; however, the total number of daughter cysts was also collected and used as an outcome measurement. When there was a discrepancy among the 3 imaging techniques regarding the number of mother cysts, the correct number was considered to be what the majority of imaging modalities indicated. Papilla and nodule were considered to be one type of structure due to the difficulty in differentiating between the two using the three imaging modalities. Pathology was regarded as the gold standard for a definitive diagnosis of different types of PCNs.

**Statistical analysis**

All of the calculations were performed using SPSS 17.0. Quantitative data, such as cystic size, are expressed as the mean or median; differences were tested using a t-test or a nonparametric test. Count data, such as the number of daughter cysts, and PCNs, were tested using Fisher’s exact test or χ². A P value < 0.05 was considered statistically significant.

**RESULTS**

Of the 73 patients who underwent surgery, 68 had confirmed PCNs and 5 had non-neoplastic cystic lesions. According to pathologic diagnoses, 27 patients had SCNs, 23 had MCNs, 6 had IPMNs, 9 had SPNs, 1 had NEN, and 2 had cystadenocarcinomas.

The baseline characteristics of the 68 enrolled patients, of whom 52 were female and 16 were male, are provided in Table 1. Twenty-four cysts were located in the head/uncinate of the pancreas and 43 in the body/tail; one patient had multiple cysts. All 68 enrolled patients underwent EUS, whereas only 52 patients underwent CT and 64 patients underwent MRI.

**Comparison of diagnostic value of the three imaging modalities in PCNs**

In the 68 PCNs confirmed by pathology, CT was able to differentiate PCNs from other PCLs with a sensitivity of 73.1% (38/52) and a diagnostic rate of 17.3% (9/52) for differentiating the specific type of PCN; MRI was able to differentiate PCNs from other PCLs with a sensitivity of 81.3% (52/64) and a diagnostic rate of 20.3% (13/64) for differentiating the specific type of PCN; and EUS was able to differentiate PCNs from other PCLs with a sensitivity of 98.5% (67/68) and a diagnostic rate of 92.6% (63/68) for differentiating the specific type of PCN. The diagnostic sensitivity of EUS was higher than those of both CT (P < 0.001) and MRI (P = 0.001). The ability of EUS to specifically classify PCNs was also better than those of both CT (P < 0.001) and MRI (P < 0.001) (Figure 1).

**PCN size**

Cyst size was assessed by CT for 52 cysts, by MRI for 65 cysts, and by EUS for 69 cysts. One patient had two separate cysts shown using both MRI and EUS. The mean size was 42.0 mm (14.0-97.0 mm) by CT, 38.0 mm (13.0-128.0 mm) by MRI, and 42.5 mm
concordance in 96.2% (50/52) of the cases among the 52 patients who underwent CT plus EUS. Among the 64 patients who underwent EUS in addition to MRI, the diagnostic concordance rate was 100.0% (64/64).

A mother cyst might consist of several daughter cysts. The patient with multiple cysts was excluded when evaluating the ability of there examinations in demonstration of daughter cyst. EUS was shown to be better than CT in evaluating the number of daughter cysts in the mother cysts ($P = 0.003$). There was no difference between EUS and MRI in evaluating the presence of mother-daughter cysts ($P = 0.254$); however, EUS showed daughter cysts more clearly and more accurately assessed the number of daughter cysts (Table 2 and Figure 2).

Detection rates of papilla/nodule, septum, and pancreatic cystic dilatation in PCNs

The papilla/nodule detection rate by EUS was as high as 35.3% (24/68), which was much higher compared to the detection rates of CT (5.8%, 3/52) and MRI (6.3%, 4/64). The detection rate of septum by EUS (60.3%, 41/68) was higher than those of both CT (34.6%, 18/52) and MRI (46.9%, 30/64). The detection rate (13.0-100.0 mm) by EUS. There was no statistically significant difference in the evaluation of cyst size using EUS and CT ($P = 0.646$) or MRI ($P = 0.587$).

Number of PCNs

The number of PCNs diagnosed by EUS and CT was in pathological diagnosis of suspected PCNs by imaging

Pathological diagnosis of suspected PCNs by imaging

Table 1  Baseline characteristics of the 68 enrolled patients

| Characteristic          | No. of patients (n = 68) |
|-------------------------|--------------------------|
| Sex                     | Male: 52, Female: 16     |
| Age, mean ± SD, yr      | 46.3 ± 14.6              |
| Location                | Head/uncinate: 24, Body/tail: 43, Others: 1 |
| Examination             | CT: 52, MRI: 64, EUS: 68 |
| Pathological diagnosis  | SCN: 27, MCN: 23, IPMN: 6, SPN: 9, NEN: 1, Cystadenocarcinomas: 2 |

Du C et al. Assessment of detailed structures of PCNs

Figure 1 Diagnosis of pancreatic cystic neoplasms by pathology and imaging.
of pancreatic cystic dilatation by EUS was 11.7% (8/68), compared with 21.2% (11/52) detected by CT and 21.9% (14/64) by MRI; however, there was no significant difference in the pancreatic cystic dilatation detection rate between EUS and CT ($P = 0.163$) or MRI ($P = 0.119$). EUS was able to reveal a pancreatic duct even when it was not dilated. The visualization rate of EUS for a normal pancreatic duct was 100.0%, whereas the visualization rate for a normal pancreatic duct using either CT or MRI were less than 10%. The comparison of detailed PCN characteristics as shown by CT, MRI, and EUS is shown in Table 3.

### Comparison of characteristics between SCNs and MCNs by EUS

The papilla/nodule detection rate, septum detection rate, and dilated pancreatic duct detection rate of SCNs by EUS were 14.8% (4/27), 81.5% (22/27), and 14.8% (4/27), respectively. For MCNs, the papilla/nodule detection rate, septum detection rate, and dilated pancreatic duct detection rate were 47.8% (11/23), 56.5% (13/23), and 13.0% (3/23), respectively (Table 4). The presence of papillae/nodules seemed to be more common in MCNs than in SCNs ($P = 0.011$). There was no difference in the detection rates of a septum or a dilated pancreatic duct between SCNs and MCNs using EUS.

### DISCUSSION

The overall five-year survival rate of pancreatic cancer is approximately 5%\cite{17}, however, the prognoses of different types of PCNs vary. SCNs are regarded as benign with a rare possibility of malignant transformation, whereas MCNs and IPMNs are considered to have a malignant potential\cite{18-20}. SPNs are low grade malignant lesions\cite{21}. Therefore, timely and accurate diagnosis of PCNs is particularly important to prevent the progression of cystic neoplasms to cancer. Whether or not EUS imaging provides accurate diagnostic information regarding pancreatic cysts is controversial\cite{7,11,22-29}.

The results of our study indicate that EUS was the optimal diagnostic method in distinguishing non-neoplastic cysts from PCNs and in characterizing the PCNs, outperforming both CT and MRI. Similarly,
While the images seen on CT and MRI are static, EUS allows for dynamic observation and high spatial resolution, which results in a more accurate estimation of the total number of daughter cysts in a mother cyst. In our study, EUS, CT, and MRI performed similarly in their ability to evaluate the number of PCNs; however, EUS was clearly more capable in determining the number of daughter cysts when compared to using CT. The detection of daughter cysts using MRI was similar to that of EUS. However, when there were more than four daughter cysts, it was more difficult to accurately count them with MRI, whereas EUS did well when counting between four and ten daughter cysts.

The papilla/nodule detection rate by EUS in our study was shown to be much higher than those by both CT and MRI. Previously, Lu et al.\(^{[23]}\) also showed that EUS was valuable in the characterization of mural nodules. The ability to detect a papilla/nodule is an important factor in the differentiation of an IPMN and its possible malignant potential. A previous study suggested that EUS had no advantages over MRI in identifying mural nodules, with a detection rate of 23% by pathology\(^{[34]}\). However, this study focused on PCLs and included 5% of pseudocysts. Additionally, this study only took mural nodules into consideration. These reasons may contribute to the different results. EUS demonstrated an advantage over CT in septum detection in our study, which is supported by a previous study\(^{[23]}\). Detection of a septum helps to differentiate a cystic neoplasm from a true cyst and a pseudocyst. No differences were found in the ability of EUS, CT, and MRI to detect pancreatic cystic dilatation. However, the rate of visualization of a normal pancreatic duct by EUS was 100%, while it was less than 10% using CT or MRI. The low detection rate of the pancreatic duct by EUS may be due to the fact that we did not measure the maximum diameter of the pancreatic duct during dynamic observation. In the field of vision in which the view of a cyst was the best, the pancreatic duct may not be clear or its diameter might not be at its maximum.

The septum detection rate and the cystic dilatation detection rate in SCNs were similar to those in MCNs. Previous reports also suggested that there were no significant differences between SCNs and MCNs in terms of mural nodules; however, only a small number of patients were included in these studies\(^{[35]}\), which could explain why the results of our research suggest otherwise. Our study suggests that EUS has some advantages.

---

**Table 3** Comparison of detection rates of papilla/nodule, septum, and pancreatic cystic dilatation in pancreatic cystic neoplasms by computed tomography, magnetic resonance imaging, and endoscopic ultrasound

|                  | CT         | MRI        | EUS        | P value  |
|------------------|------------|------------|------------|----------|
| Papilla/nodule detection rate | 5.80% (3/52) | 6.30% (4/64) | 35.30% (24/68) | 0.000*   |
| Septum detection rate           | 34.60% (18/52) | 46.90% (30/64) | 60.30% (41/68) | 0.005*   |
| Dilated pancreatic duct detection rate | 21.20% (11/52) | 21.90% (14/64) | 11.70% (8/68)  | 0.163    |

*P < 0.05, there is statistical significance between each other. EUS: Endoscopic ultrasound; CT: Computed tomography; MRI: Magnetic resonance imaging.

**Table 4** Comparison of the characteristics of pancreatic cystic neoplasms between serous cystic neoplasms and mucinous cystic neoplasms by endoscopic ultrasound

|                  | SCNs       | MCNs       | P value  |
|------------------|------------|------------|----------|
| Papilla/nodule detection rate | 14.80% (4/27) | 47.80% (11/23) | 0.011*   |
| Septum detection rate           | 81.50% (22/27) | 56.50% (13/23) | 0.055    |
| Duct dilatation detection rate  | 13.80% (4/27) | 13.00% (1/23)  | 0.857    |

*P < 0.05, there is statistical significance between each other. EUS: Endoscopic ultrasound; SCNs: Serous cystic neoplasms; MCNs: Mucinous cystic neoplasms.

Lu et al.\(^{[23]}\) found that EUS was able to identify PCNs better when compared to using CT and MRI. In our study, the sensitivity of EUS for diagnosing PCNs and the accuracy for characterizing PCNs were higher than those previously reported\(^{[23,30,31]}\). In our study, almost all of the patients had undergone CT or MRI prior to undergoing EUS; it is possible that the MRI or CT imaging reports may have influenced the diagnosis by EUS. Additionally, although we did not take the results of cystic fluid evaluation into consideration, the final diagnosis was made after fine needle aspiration (FNA) following EUS evaluation. The color and viscosity of the aspirate may have influenced the EUS report. Lastly, the endoscopists in the present study were experienced in EUS, particularly in PCNs, which could have had an effect on the final diagnosis by EUS.

In agreement with Leeds et al.\(^{[2]}\), our study showed that there were no significant differences between EUS and CT, or between EUS and MRI, in evaluating PCN size. However, this result is inconsistent with the results published by Maimone et al.\(^{[31]}\), who demonstrated that there was considerable variation in size estimates of pancreatic cysts among the imaging techniques and suggested that these discrepancies should be taken into account when making management decisions. Another previous study by Lee et al.\(^{[11]}\) indicated that CT was the best imaging modality to use, in comparison to MRI and EUS, with regard to evaluating PCN size. The discrepancy between our results and previously published results could be due to the experience of the operator; EUS requires experienced and skilled operators.

Some of the PCNs were mother-daughter cysts. While the images seen on CT and MRI are static, EUS allows for dynamic observation and high spatial resolution, which results in a more accurate estimation of the total number of daughter cysts in a mother cyst. In our study, EUS, CT, and MRI performed similarly in their ability to evaluate the number of PCNs; however, EUS was clearly more capable in determining the number of daughter cysts when compared to using CT. The detection of daughter cysts using MRI was similar to that of EUS. However, when there were more than four daughter cysts, it was more difficult to accurately count them with MRI, whereas EUS did well when counting between four and ten daughter cysts.

The papilla/nodule detection rate by EUS in our study was shown to be much higher than those by both CT and MRI. Previously, Lu et al.\(^{[23]}\) also showed that EUS was valuable in the characterization of mural nodules. The ability to detect a papilla/nodule is an important factor in the differentiation of an IPMN and its possible malignant potential. A previous study suggested that EUS had no advantages over MRI in identifying mural nodules, with a detection rate of 23% by pathology\(^{[34]}\). However, this study focused on PCLs and included 5% of pseudocysts. Additionally, this study only took mural nodules into consideration. These reasons may contribute to the different results. EUS demonstrated an advantage over CT in septum detection in our study, which is supported by a previous study\(^{[23]}\). Detection of a septum helps to differentiate a cystic neoplasm from a true cyst and a pseudocyst. No differences were found in the ability of EUS, CT, and MRI to detect pancreatic cystic dilatation. However, the rate of visualization of a normal pancreatic duct by EUS was 100%, while it was less than 10% using CT or MRI. The low detection rate of the pancreatic duct by EUS may be due to the fact that we did not measure the maximum diameter of the pancreatic duct during dynamic observation. In the field of vision in which the view of a cyst was the best, the pancreatic duct may not be clear or its diameter might not be at its maximum.

The septum detection rate and the cystic dilatation detection rate in SCNs were similar to those in MCNs. Previous reports also suggested that there were no significant differences between SCNs and MCNs in terms of mural nodules; however, only a small number of patients were included in these studies\(^{[35]}\), which could explain why the results of our research suggest otherwise. Our study suggests that EUS has some advantages.

---

**Table 3** Comparison of detection rates of papilla/nodule, septum, and pancreatic cystic dilatation in pancreatic cystic neoplasms by computed tomography, magnetic resonance imaging, and endoscopic ultrasound

|                  | CT         | MRI        | EUS        | P value  |
|------------------|------------|------------|------------|----------|
| Papilla/nodule detection rate | 5.80% (3/52) | 6.30% (4/64) | 35.30% (24/68) | 0.000*   |
| Septum detection rate           | 34.60% (18/52) | 46.90% (30/64) | 60.30% (41/68) | 0.005*   |
| Dilated pancreatic duct detection rate | 21.20% (11/52) | 21.90% (14/64) | 11.70% (8/68)  | 0.163    |

*P < 0.05, there is statistical significance between each other. EUS: Endoscopic ultrasound; CT: Computed tomography; MRI: Magnetic resonance imaging.

**Table 4** Comparison of the characteristics of pancreatic cystic neoplasms between serous cystic neoplasms and mucinous cystic neoplasms by endoscopic ultrasound

|                  | SCNs       | MCNs       | P value  |
|------------------|------------|------------|----------|
| Papilla/nodule detection rate | 14.80% (4/27) | 47.80% (11/23) | 0.011*   |
| Septum detection rate           | 81.50% (22/27) | 56.50% (13/23) | 0.055    |
| Duct dilatation detection rate  | 13.80% (4/27) | 13.00% (1/23)  | 0.857    |

*P < 0.05, there is statistical significance between each other. EUS: Endoscopic ultrasound; SCNs: Serous cystic neoplasms; MCNs: Mucinous cystic neoplasms.
in the diagnosis and classification of PCNs. Its ability to provide a clear, dynamic view of PCNs with high spatial resolution may contribute to its diagnostic value. EUS can also be used to guide FNA to collect cystic fluid and cystic tissue for biochemical analysis, cytology analysis, and pathological examination, which may also contribute to the diagnosis and the classification of PCNs.\textsuperscript{[26,27]} EUS-guided SpyGlass can aid in the diagnosis and classification of PCNs.\textsuperscript{[38]} EUS-guided ethanol and radiofrequency ablation are promising and minimally invasive treatments for patients with PCNs.\textsuperscript{[29-45]} However, there are limitations to EUS. It is operator-dependent, which could result in inconsistent results among different operators.\textsuperscript{[46]} EUS may also not be readily available in some hospitals. EUS is also an invasive examination that poses a higher risk than CT and MRI. Although this prospective study provides a relatively large sampling of patients, it is not without its limitations. Not all of the patients underwent all three imaging examinations. Additionally, very few patients were diagnosed with IPMNs and SPNs; additional patients are needed to provide more generalizable information regarding the use of EUS in these subtypes.

EUS was shown in this study to differentiate PCNs from other PCLs and characterize the PCN subtype far better than either CT or MRI. The measurement of cystic size using EUS was shown to be no different than when using CT and MRI. However, EUS was more accurate when determining the number of daughter cysts in mother cysts and had a higher detection rate of septum when compared to CT. The papilla/nodule detection rate and the visualization rate for a normal pancreatic duct by EUS were both superior when compared to using the other two diagnostic methods. These results indicate that EUS can be used to gain structural information regarding PCNs and is a valuable diagnostic tool.

**COMMENTS**

**Background**

About 60% of pancreatic cystic lesions (PCLs) are cystic neoplasms which have the potential to be malignant. The prevalence of pancreatic cystic neoplasms (PCNs) has been reported to range widely, from 0.21%-24.3%. Because some PCNs have a malignant potential, it is important to differentiate them from other non-neoplastic cysts and benign PCNs. Appropriate diagnosis with imaging modalities may help decide subsequent treatments and is thus extremely important.

**Research frontiers**

Computed tomography (CT) and magnetic resonance imaging (MRI) are most frequently used in the diagnosis of PCLs. However, endoscopic ultrasound (EUS) has an advantage over CT and MRI in distinguishing between benign pancreatic cystic lesions and malignant or potentially malignant ones. In our study, the inner detailed structures were well studied among three imaging modalities, which have not been reported in other studies.

**Innovations and breakthroughs**

The authors found that EUS did best in distinguishing non-neoplastic cysts from PCNs and characterize PCNs. There are many studies about the diagnostic value of imaging in PCLs, several studies are about its ability of differentiating PCNs from other PCLs. The measurement of cystic size of EUS has no difference from CT and MRI but EUS does better on judging the number of son-cyst in mother-cyst and has higher detection rates of septum than CT. Several studies compared imaging’s abilities of demonstrating son cysts. The papilla/nodule detection rate and visual rate for normal pancreatic duct of EUS is best among three diagnostic methods. We also found that papilla/nodule seemed to be more common in MCN than serous cystic neoplasms.

**Applications**

EUS is a valuable tool to help diagnose PCNs and to detail their structures. The patients suspected of having PCNs should be suggested to undergo EUS. This study provides additional evidence supporting the advantages of EUS compared with CT and MRI.

**Terminology**

A single tumor with unilocular or multilocular cysts (cyst in cyst) and cysts forming a cluster around a central scar (cyst on cyst) were both called a mother-daughter cyst. The mother-daughter cyst was regarded as a cyst.

**Peer-review**

This study evaluated the advantages of EUS in the assessment of detailed structures of pancreatic cystic neoplasms compared with CT and MRI. The manuscript is interesting.

**REFERENCES**

1. Yoon WJ, Brugge WR. Endoscopic ultrasound and pancreatic cystic lesions-diagnostic and therapeutic applications. *Endosc Ultrasound* 2012; 1: 75-79 [PMID: 24949341 DOI: 10.7178/ eus.02.004]
2. Laffan TA, Horton KM, Klein AP, Berlanstein B, Siegelman SS, Kawamoto S, Johnson PT, Fishman EK, Hruban RH. Prevalence of unsuspected pancreatic cysts on MDCT. *AJR Am J Roentgenol* 2008; 191: 802-807 [PMID: 18716113 DOI: 10.2214/AJR.07.3340]
3. Lee KS, Sekhar A, Rofsiky NM, Pedrosa I. Prevalence of incidental pancreatic cysts in the adult population on MR imaging. *Am J Gastroenterol* 2010; 105: 2079-2084 [PMID: 20354507 DOI: 10.1038/ajg.2010.122]
4. Zhang XM, Mitchell DG, Dohike M, Holland GA, Parker L. Pancreatic cysts: depiction on single-shot fast spin-echo MR images. *Radiology* 2002; 223: 547-553 [PMID: 11997566 DOI: 10.1148/radiol.2232010815]
5. Vege SS, Ziring B, Jain R, Moayyedi P. American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. *Gastroenterology* 2015; 148: 819-822, quiz 12-13 [PMID: 25803575 DOI: 10.1053/j.gastro.2015.01.015]
6. Soraida Y, Sato M, Hikita H, Hagiwara S, Sato M, Gotoh H, Kato S, Iwai T, Yamazaki T, Yatomi M, Sasano T, Ikeda H. Pancreatic cysts in general population on ultrasonography: Prevalence and development of risk score. *J Gastroenterol* 2016; 51: 1133-1140 [PMID: 26988361 DOI: 10.1007/s00535-016-1186-y]
7. Kim JH, Eun HW, Park HJ, Hong SS, Kim YJ. Diagnostic performance of MRI and EUS in the differentiation of benign from malignant pancreatic cyst and cyst communication with the main duct. *Eur J Radiol* 2012; 81: 2927-2935 [PMID: 22227264 DOI: 10.1016/j.ejrad.2011.12.019]
8. Rastegar N, Matteoni-Athayde LG, Eng J, Takahashi N, Tamm EP, Mortele KJ, Syngal S, Margolis D, Lennon AM, Wolfgang CL, Fishman EK, Hruban RH, Goggins M, Canto MI, Kamel IR. Incremental value of secretin-enhanced magnetic resonance cholangiopancreatography in detecting ductal communication in a population with high prevalence of small pancreatic cysts. *Eur J Radiol* 2015; 84: 575-580 [PMID: 25619503 DOI: 10.1016/j.ejrad.2014.12.028]
9. Kauhanen S, Rinta-Kiikka I, Kemppainen J, Grönroos J, Kajander S, Seppänen M, Alanen K, Gullichsen R, Nuutila P, Ovaska J. Accuracy of 18F-FDG PET/CT, Multidetector CT, and MR...
Imaging in the Diagnosis of Pancreatic Cysts: A Prospective Single-Center Study. *J Nucl Med* 2015; 56: 1163-1168 [PMID: 26045314 DOI: 10.2967/jnm.114.148940]

Yoshioka T, Shiogekawa M, Yamai T, Suda T, Kegasawa T, Iwashashi K, Ikewaka K, Sakamori R, Yakushijin T, Hiramatu N, Tatsumi T, Takehara T. The safety and benefit of pancreatic juice cytology under ERCP in IPMN patients. *Pancreatology* 2016; 16: 1020-1027 [PMID: 27567445 DOI: 10.1016/j.pan.2016.08.009]

Lee YS, Paik KH, Kim HW, Lee JC, Kim J, Hwang JH. Comparison of Endoscopic Ultrasonography, Computed Tomography, and Magnetic Resonance Imaging for Pancreatic Cystic Lesions. *Medicine* (Baltimore) 2015; 94: e1666 [PMID: 26469901 DOI: 10.1097/MD.00000000000001666]

Jani N, Bani Hani M, Schullid RD, Hruban RH, Cunningham SC. Diagnosis and management of cystic lesions of the pancreas. *Diagn Ther Endosc* 2011; 2011: 478913 [PMID: 21904442 DOI: 10.1155/2011/478913]

Jones MJ, Buchanan AS, Neal CP, Dennison AR, Metcalfe MS, Garcea G. Imaging of indeterminate pancreatic cystic lesions: a systematic review. *Pancreatology* 2013; 13: 436-442 [PMID: 23890144 DOI: 10.1016/j.pan.2013.05.007]

Brugge WR. Diagnosis and management of cystic lesions of the pancreas. *J Gastrointest Oncol* 2015; 6: 357-388 [PMID: 26261743 DOI: 10.3978/j.issn.2078-6891.2015.05.07]

Tsujino T, Yan-Lin Huang J, Nakai Y, Samarasesa JB, Lee JG, Chang KJ. In vivo identification of pancreatic cystic neoplasms with needle-based confocal laser endomicroscopy. *Best Pract Res Clin Gastroenterol* 2015; 29: 601-610 [PMID: 23631305 DOI: 10.1016/j.bpcergo.2015.06.006]

Bhutani MS. Role of endoscopic ultrasound for pancreatic cystic lesions: Past, present, and future! *Endosc Ultrasound* 2015; 4: 273-275 [PMID: 26643692 DOI: 10.4103/2303-9027.170400]

Faleasca M, Kim M, Casari I. Pancreatic cancer: Current research and future directions. *Biochim Biophys Acta* 2016; 1865: 123-132 [PMID: 26794394 DOI: 10.1016/j.bcbcar.2016.01.001]

Scheiman JM, Hwang JH, Moayyedi P. American gastroenterological association technical review on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. *Gastroenterology* 2015; 148: 824-848.e22 [PMID: 25805376 DOI: 10.1053/j.gastro.2015.01.014]

Tanaka M, Fernández-del Castillo C, Adsay V, Chahla E, Levy M. Role of endoscopic ultrasound for pancreatic cystic adenocarcinoma and intraductal papillary mucinous tumor. *Diagn Ther Endosc* 2011; 2011: 478913 [PMID: 21904442 DOI: 10.1155/2011/478913]

Jani N, Bani Hani M, Schullid RD, Hruban RH, Cunningham SC. Diagnosis and management of cystic lesions of the pancreas. *Diagn Ther Endosc* 2011; 2011: 478913 [PMID: 21904442 DOI: 10.1155/2011/478913]

Jones MJ, Buchanan AS, Neal CP, Dennison AR, Metcalfe MS, Garcea G. Imaging of indeterminate pancreatic cystic lesions: a systematic review. *Pancreatology* 2013; 13: 436-442 [PMID: 23890144 DOI: 10.1016/j.pan.2013.05.007]

Brugge WR. Diagnosis and management of cystic lesions of the pancreas. *J Gastrointest Oncol* 2015; 6: 357-388 [PMID: 26261743 DOI: 10.3978/j.issn.2078-6891.2015.05.07]

Tsujino T, Yan-Lin Huang J, Nakai Y, Samarasesa JB, Lee JG, Chang KJ. In vivo identification of pancreatic cystic neoplasms with needle-based confocal laser endomicroscopy. *Best Pract Res Clin Gastroenterol* 2015; 29: 601-610 [PMID: 23631305 DOI: 10.1016/j.bpcergo.2015.06.006]

Bhutani MS. Role of endoscopic ultrasound for pancreatic cystic lesions: Past, present, and future! *Endosc Ultrasound* 2015; 4: 273-275 [PMID: 26643692 DOI: 10.4103/2303-9027.170400]

Faleasca M, Kim M, Casari I. Pancreatic cancer: Current research and future directions. *Biochim Biophys Acta* 2016; 1865: 123-132 [PMID: 26794394 DOI: 10.1016/j.bcbcar.2016.01.001]

Scheiman JM, Hwang JH, Moayyedi P. American gastroenterological association technical review on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. *Gastroenterology* 2015; 148: 824-848.e22 [PMID: 25805376 DOI: 10.1053/j.gastro.2015.01.014]

Tanaka M, Fernández-del Castillo C, Adsay V, Chahla E, Levy M. Role of endoscopic ultrasound for pancreatic cystic adenocarcinoma and intraductal papillary mucinous tumor. *Diagn Ther Endosc* 2011; 2011: 478913 [PMID: 21904442 DOI: 10.1155/2011/478913]
Du C et al. Assessment of detailed structures of PCNs

Ethanol lavage of pancreatic cystic lesions: initial pilot study. *Gastrointest Endosc* 2005; 61: 746-752 [PMID: 15855986]

40 Caillol F, Poincloux L, Bories E, Cruzille E, Pesenti C, Darcha C, Poizat F, Monges G, Raoul JL, Bommelaer G, Giovannini M. Ethanol lavage of 14 mucinous cysts of the pancreas: A retrospective study in two tertiary centers. *Endosc Ultrasound* 2012; 1: 48-52 [PMID: 24949335 DOI: 10.7178/eus.01.008]

41 Park JK, Song BJ, Ryu JK, Paik WH, Park JM, Kim J, Lee SH, Kim YT. Clinical Outcomes of Endoscopic Ultrasonography-Guided Pancreatic Cyst Ablation. *Pancreas* 2016; 45: 889-894 [PMID: 26765962 DOI: 10.1097/MPA.0000000000000567]

42 Oh HC, Seo DW, Song TJ, Moon SH, Park DH, Soo Lee S, Lee SK, Kim MH, Kim J. Endoscopic ultrasonography-guided ethanol lavage with paclitaxel injection treats patients with pancreatic cysts. *Gastroenterology* 2011; 140: 172-179 [PMID: 20950614 DOI: 10.1053/j.gastro.2010.10.001]

43 Gan SI, Thompson CC, Lauwers GY, Bounds BC, Brugge WR.

44 DeWitt J, Mcgreevy K, Schmidt CM, Brugge WR. EUS-guided ethanol versus saline solution lavage for pancreatic cysts: a randomized, double-blind study. *Gastrointest Endosc* 2009; 70: 710-723 [PMID: 19577745 DOI: 10.1016/j.gie.2009.03.1173]

45 DeWitt J, DiMaio CJ, Brugge WR. Long-term follow-up of pancreatic cysts that resolve radiologically after EUS-guided ethanol ablation. *Gastrointest Endosc* 2010; 72: 862-866 [PMID: 20883866 DOI: 10.1016/j.gie.2010.02.039]

46 Ahmad NA, Kochman ML, Brensinger C, Brugge WR, Faigel DO, Gress FG, Kimmey MB, Nickl NJ, Savides TJ, Wallace MB, Wiersema MJ, Ginsberg GG. Interobserver agreement among endosonographers for the diagnosis of neoplastic versus non-neoplastic pancreatic cystic lesions. *Gastrointest Endosc* 2003; 58: 59-64 [PMID: 12838222 DOI: 10.1067/mge.2003.298]
